You are here: Industry Insights > Aimovig

News List

Aimovig®displays superiority over topiramate in migraine study EuropeanPharmaceuticalReview
November 11, 2021
Amgen has announced new data from the HER-MES Phase IV study, the first and only head-to-head study of Aimovig® (erenumab-aooe), a calcitonin gene-related peptide (CGRP) inhibitor...
NICE u-turn on Novartis' migraine drug Aimovig pharmatimes
December 15, 2020
In a rare move, NICE has reconsidered its position on Novartis migraine prevention treatment Aimovig (erenumab), now recommending the drug's NHS use in a Final Appraisal Document (FAD) on the back of further analysis submitted by the company.
Aimovig approved by EU for migraine prevention europeanpharmaceuticalreview
April 19, 2019
Researchers found that more than one quarter (26 per cent) of patients taking Aimovig 70mg were migraine free after month 15…
NICE declines to endorse Novartis’ pricey migraine drug Aimovig pharmaceutical-technology
January 14, 2019
National Institute for Health and Care Excellence (NICE) in the UK has rejected Novartis’ migraine prevention drug Aimovig (erenumab) saying the drug is not a cost-effective use of the NHS resources.....
Novartis’ Aimovig fails to win NICE backing amid tight migraine fight with Lilly, Teva fiercepharma
January 13, 2019
Separately, the Institute for Clinical and Economic Review previously concluded that Aimovig’s use is cost-effective but only after patients try “existing preventive treatments, which are far less expensive.”
NICE rejects Novartis’ migraine prevention drug Aimovig pharmaphorum
January 10, 2019
Some migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are facing disappointment after NICE rejected it in draft guidance.
World’s first migraine-specific prevention treatment available in Singapore biospectrumasia
November 26, 2018
Singapore – Novartis announced that the Health Sciences Authority (HSA) has approved Aimovig (erenumab) in Singapore for the prevention of migraine in adults.
Lilly’s Emgality nabs third-to-market migraine nod but aims to be 'treatment of choice' in CGRP fiercepharma
September 29, 2018
Lilly will provide 12 months of Emgality to patients for free under an access program, an executive said. (Eli Lilly)
A new era for migraine patients cphi-online
August 07, 2018
EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.
Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals? fiercepharma
July 30, 2018
Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that by handing out a lot of the product for free.

Previous page 1 2 Next page